J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors Original Research Article

A new class of 4-acetamidopiperidine derivatives has been synthesized and investigated for human muscarinic receptor subtype selectivity. Introduction of a hydrocarbon chain of appropriate length into the piperidine nitrogen of the racemic N-(piperidin-4-yl)-2-cyclobutyl-2-hydroxy-2-phenylacetamide platform conferred up to 70-fold selectivity for human muscarinic M3 receptors over M2 receptors. Subsequent synthetic derivatizations resulted in highly potent M3 receptor antagonists with selectivity greater than two orders of magnitude for M3 over M2 receptors, from which the analogue was selected. Preparation of both enantiomers of led to the identification of (2R)-N-[1-(4-methyl-3-pentenyl)piperidin-4-yl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide (J-104129, ), which exhibited 120-fold selectivity for M3 receptors (Ki=4.2 nM) over M2 receptors (Ki=490 nM). In isolated rat trachea, potently and specifically antagonized acetylcholine (ACh)-induced responses with a KB value of 3.3 nM. The highly subtype-selective profile was also seen in isolated rat tissue assays (50-fold) and in anesthetized rats (>250-fold). Oral administration of J-104129 () antagonized ACh-induced bronchoconstriction with an ED50 value of 0.58 mg/kg in rats. Thus, J-104129 () may effectively facilitate bronchodilation in the treatment of obstructive airway disease.